Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

Launched by GENE SOLUTIONS · Dec 4, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how changes in circulating tumor DNA (ctDNA) can help doctors predict how well patients with advanced non-small cell lung cancer (NSCLC) will respond to a type of treatment called Tyrosine Kinase Inhibitors (TKIs). The researchers want to see if measuring ctDNA levels can indicate whether a patient’s cancer is getting better, staying the same, or worsening. They will also compare the ctDNA results with standard imaging tests to see if they can better understand a patient's response to the treatment and how long they may live without the cancer progressing.

To participate in this trial, patients need to have a diagnosis of advanced NSCLC and be eligible for TKI therapy, either as their first or second line of treatment. They should have a sample of their tumor available for testing and must agree to follow the study guidelines. Patients who have already started TKI or chemotherapy before joining the study will not be eligible. Those who join the trial can expect to provide blood samples for ctDNA testing, and they will be monitored closely to see how well the treatment is working. This study is currently recruiting patients, and it aims to help improve future treatments for those facing advanced lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients are diagnosed with advanced non-small cell lung cancer and indicated for TKI (first or second line). TKI combined with chemotherapy is allowed.
• • FFPE/FNA sample is available.
• • Compliant with treatment protocol.
• • Patients consented to participate in the study.
• Exclusion Criteria:
• • Patients already started TKI before enrollment.
• • Patients already started chemotherapy before enrollment.
• • Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
• • Patients did not agree to participate in the studies.